AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, completed the acquisition of TeneoTwo, a biotechnology firm, for $1.3bn. "By redirecting the body's natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes. We believe this innovative molecule, which was designed to optimise the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting," Anas Younes, AstraZeneca Senior Vice President Haematology R&D.